Is finerenone (Anti-mineralocorticoid receptor antagonist) used as a first-line treatment for hypertension?

Finerenone for Hypertension

Finerenone is not recommended as a first-line treatment for hypertension, but rather is indicated specifically for patients with type 2 diabetes and chronic kidney disease with albuminuria as an additional risk-based therapy after first-line agents. 1

Role of Finerenone in Treatment Algorithms

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (ns-MRA) with proven clinical kidney and cardiovascular benefits, but its use is specifically positioned in treatment algorithms for patients with:

• Type 2 diabetes
• Chronic kidney disease
• Albuminuria (ACR ≥30 mg/g)
• Normal serum potassium concentration
• Already on maximum tolerated dose of RAS inhibitor (ACEi or ARB)

First-Line Treatments for Hypertension

According to current guidelines, first-line therapy for hypertension should be:

• For patients with albuminuria: ACE inhibitor or ARB should be first-line therapy 1
• For patients without albuminuria: Dihydropyridine calcium channel blocker or diuretic can be considered as first-line options 1

Positioning of Finerenone in Treatment Algorithm

Finerenone is positioned as an additional risk-based therapy rather than first-line treatment for hypertension:

1. First-line drugs:

   • ACEi or ARB (at maximum tolerated dose) for patients with hypertension and albuminuria
   • Dihydropyridine CCB or diuretic for those without albuminuria

2. Additional therapy (if needed to reach BP targets):

   • Add dihydropyridine CCB and/or diuretic

3. Risk-based additional therapy:

   • Add finerenone if patient has T2D, CKD with albuminuria (ACR ≥30 mg/g), and normal potassium 1

4. For resistant hypertension:

   • Consider steroidal MRA (spironolactone) if eGFR ≥45 ml/min/1.73m² 1

Clinical Evidence for Finerenone

Finerenone has demonstrated significant benefits in patients with T2D and CKD:

• Reduced composite kidney outcomes (kidney failure, sustained decrease ≥40% in eGFR, or death from kidney causes) by 18% 1
• Reduced composite cardiovascular outcomes by 14% 1, 2
• Reduced new-onset heart failure by 32% 2
• Reduced blood pressure modestly, but this accounted for only about 13% of its cardiorenal benefits 3

Important Considerations for Finerenone Use

• Initiation criteria: eGFR ≥25 ml/min/1.73m² and serum potassium ≤5.0 mmol/l 1
• Dosing: Start at 10 mg daily for eGFR 25-60 ml/min/1.73m² and 20 mg daily for eGFR >60 ml/min/1.73m² 1
• Monitoring: Check potassium 4 weeks after dose changes and regularly during treatment 1
• Main adverse effect: Hyperkalemia (14% vs. 6.9% with placebo) 1

Clinical Pitfalls to Avoid

• Don't use as first-line hypertension treatment: Finerenone is not approved or recommended as initial therapy for hypertension without the specific indications noted above 1
• Monitor for hyperkalemia: Risk increases as renal function declines; starting treatment early when eGFR is maintained may reduce side effects 4
• Don't confuse with steroidal MRAs: Finerenone has different tissue distribution and effects compared to spironolactone and eplerenone 4, 5
• Consider combination therapy: Simultaneous use of RAS inhibitors, finerenone, and SGLT2 inhibitors appears promising in appropriate patients with T2D and CKD 4

In summary, finerenone is not a first-line agent for hypertension management but rather a specialized therapy for patients with T2D, CKD, and albuminuria who are already on RAS inhibitors, with demonstrated benefits for cardiorenal outcomes beyond blood pressure control alone.